Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06531395 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
A Phase 2 study, sponsored by Kiniksa Pharmaceuticals International.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06531395 is a Phase 2 study that was terminated before completion, run by Kiniksa Pharmaceuticals International. The registered enrollment target is 3 participants.
The verdict
NCT06531395, a Phase 2 study, was terminated before completion, sponsored by Kiniksa Pharmaceuticals International.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Primary objective of the study is to evaluate the effect of abiprubart on an established systemic disease activity measure for Sjögren's Disease.
Interventions
- DRUG Placebo
- DRUG Abiprubart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-07-17 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06531395
The ClinicalTrials.gov registry entry for NCT06531395 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kiniksa Pharmaceuticals International, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06531395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06531395 about?
NCT06531395 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease". Primary objective of the study is to evaluate the effect of abiprubart on an established systemic disease activity measure for Sjögren's Disease.
What is the current status of trial NCT06531395?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2024-07-17. Estimated completion is 2025-05-01.
What interventions are being tested in trial NCT06531395?
The interventions under investigation include: Placebo (DRUG), Abiprubart (DRUG).
Who is sponsoring clinical trial NCT06531395?
This trial is sponsored by Kiniksa Pharmaceuticals International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.